Sai Life Sciences logo

Sai Life Sciences financials: balance sheet, profit and loss, cash flow

NSE: SAILIFEBSE: 544306Pharmaceuticals & BiotechnologySmall Cap

Sai Life Sciences Limited · Face value ₹1 · Listed Dec 2024 · Issue price ₹549
Last close ₹1,557.50up ₹61.80 (4.13%)BSE ₹1,559.70

Share price at the NSE close on 30 Oct 2026. Previous close ₹1,495.70.

30 Oct: open ₹1,499.40, high ₹1,568.00, low ₹1,496.00

52-week range of traded prices to 30 Oct 2026
₹783.85Low, 5 Feb 2026₹1,697.00High, 9 Sep 2026
Market cap
₹33,084 Cr329th largest listed
P/E
91.46
P/B
13.32
Dividend yield
Nonein the last 12 months
ROE
15.7%
ROCE
18.7%
Debt to equity
0.04
Volume, NSE
12,62,08247.3% delivered

Sai Life Sciences' financial statements for the 2 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

2 years at a glance

₹ crore, years to March.Sai Life Sciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
1,695170129Mar 252,19234995Mar 26
Peak revenue ₹2,192 Cr, year to Mar 2026; lowest ₹1,695 Cr, year to Mar 2025

Operating and net margin, per cent

  • Operating margin
  • Net margin
28.8%10.0%23.9%28.8%10.0%15.9%Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue2,192
  2. Materials and goods−571
  3. Employee costs−683
  4. Other expenses−307
  5. Operating profit631
  6. Depreciation−167
  7. Other income+49
  8. One-off items−8.0
  9. Finance costs−39
  10. Profit before tax466
  11. Tax−117
  12. Net profit349

What the company owns

  • Plant, investments and other assets₹2,944 Cr
  • Receivables₹374 Cr
  • Inventory₹151 Cr
  • Cash and bank₹111 Cr
  • Current investments₹47 Cr

What pays for it: net worth and liabilities

  • Net worth₹2,484 Cr
  • Other liabilities₹762 Cr
  • Owed to suppliers₹285 Cr
  • Borrowings₹95 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Sai Life Sciences quarterly results

₹ croreMar 2025Mar 2026Filed 14 MayJun 2026Twelve monthsFiled 6 Aug
Revenue from operations1,6952,1922,250
1,2891,5611,592
Materials and goods bought466571575
Employee costs549683702
Other expenses274307315
Operating profit before depreciation406631658
Operating margin23.9%28.8%29.3%
Materials, % of revenue27.5%26.0%25.5%
Employee costs, % of revenue32.4%31.2%31.2%
Other expenses, % of revenue16.2%14.0%14.0%
Depreciation and amortisation139167175
Operating profit after depreciation267464483
Other income374943
Finance costs763935
Profit before one-off items and tax228474491
One-off items0−8−8
Profit before tax228466483
58117122
Net profit170349362
Other comprehensive income1−21−3
Total comprehensive income171328359
Net margin10.0%15.9%16.1%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Mar 2026Filed 14 May
2,1282,484
Share capital2121
Reserves2,1082,463
12995
732834
299309
Total assets3,1603,626
1,6552,216
1,5051,411
Net debt−335−63
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Mar 2026Filed 14 May
314509
336548
−131−74
Receivables−100−15
Inventories−31−32
Payables10633
Other working capital−106−59
Tax paid−22−39
Capital spending369593
Free cash flow−55−84
−537−395
301−124
Dividends paid00
Shares bought back00
Shares issued1,0005
Net change in cash79−10
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2025Mar 2026Filed 14 May
Earnings per share₹8.83₹16.63
Diluted earnings per share₹8.61₹16.43
Book value per share₹102.12₹117.28
Shareholder yield−6.3%0.0%
Market cap at the year end (₹ crore)15,82520,532

Ratios

Consolidated, years to March.Sai Life Sciences PE ratio and valuation

RatioMar 2025Mar 2026Filed 14 May
Revenue growth–29.4%
Operating profit growth–55.6%
Net profit growth–105.1%
Earnings per share growth–88.3%
8.0%15.1%
–7.1 pts
From the net margin–4.7 pts
From asset turnover–2.6 pts
From borrowing–−0.1 pts
Return on capital employed11.8%18.0%
Cash conversion184.6%145.9%
Interest cover3.511.8
Debt to equity0.060.04
Receivable days7662
Inventory days9397
Payable days253182
Cash conversion cycle, days−83−24
Working capital days9482
Asset turnover0.540.65
Assets per rupee of net worth1.481.47
Sales per rupee of plant1.151.21
Capital spending to depreciation2.663.55
Plant being built, % of plant in use8.4%15.0%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
10.3%
Cash from operations against operating profit
80.7%
Measure3 years
Return on equity, average11.6%
Return on capital employed, average14.9%
Operating margin, average26.4%
Net margin, average13.0%
Asset turnover, average0.59
Cash conversion cycle, days, average−53
Interest cover, average7.7
Debt to equity, average0.05

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations509
Cash from investing−395
Cash from financing−124
Capital spending593
Dividends paid0
Shares bought back0
Shares issued for cash5
Borrowings raised26
Borrowings repaid59

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Altman Z-scorePublished threshold 1.8111.3013.02
Beneish M-scorePublished threshold −1.78–−2.17
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–6.93
Receivables growth less revenue growthOur threshold 0 percentage points–−24.07
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–4.44
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–7.35
Assets under construction, years of additionsOur threshold 2 years of additions–0.54
Effective tax ratePublished threshold 17.16 per cent25.2825.16
Tax charged less tax paid, % of profitOur threshold 10 percentage points15.7816.81
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
26 Feb 2026ICRA LimitedNon-fund based-Others[ICRA]A1+Review, Re-affirm218.60
26 Feb 2026ICRA LimitedFund-based-Others[ICRA]AAReview, Re-affirmStable550
14 Aug 2025India Ratings and Research Private LimitedBank loan facilitiesIND AA-; IND A1+Review, OtherPositive769
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.